Drug Trial Radar · NCT07503561
A Trial to Evaluate the Safety, Tolerability and Efficacy of AIC263029 in Kidney Transplant Recipients With BKV Infection
Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
24
Planned (sponsor's estimate)
Start
Oct 5, 2026
Primary completion
Sep 17, 2027
Study completion Dec 31, 2027
Sponsor
- Lead sponsor
- AiCuris Anti-infective Cures AGIndustry
- Sponsor type
- Industry
- First posted
- Mar 31, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to learn if AIC263029 is safe and well tolerated in adult kidney transplant recipients with BK virus (BKV) in the blood (viremia). The study will also examine how the body processes AIC263029 and whether it lowers BKV levels in the blood. Researchers will compare AIC263029 to a placebo (a look-alike injection with no active drug). Participants will be assigned by chance to receive AIC263029 or placebo and will receive weekly injections under the skin for 4 weeks. Participants will have clinic visits and blood tests during treatment and follow-up to monitor safety and measure BKV levels, and will be followed for up to about 24 weeks after treatment.
Conditions
- BK Virus Infection
- BKV Infection
- Kidney Transplant
Interventions
AIC263029Drug
AIC263029 supplied in vials for injection (110 mg/mL) and administered by subcutaneous injection; Part A uses weekly dosing over 4 weeks in planned dose cohorts (100 mg, 200 mg, 330 mg).
PlaceboDrug
Matching placebo administered by subcutaneous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Frequency and severity of treatment-emergent adverse events (TEAEs)Time frame: Day 1 to Day 30 of the dosing period.
Locations
14 sites in 1 country. Site status is shown where the registry gives one.
University of Alabama at Birmingham Hospital
Birmingham, Alabama · Recruiting
Keck Hospital of University of Southern California (USC)
Los Angeles, California · Recruiting
UCLA College of Medicine
Los Angeles, California · Recruiting
Tampa General Hospital
Tampa, Florida · Recruiting
Emory University
Atlanta, Georgia · Recruiting
University of Chicago Medical Center
Chicago, Illinois · Recruiting
University of Maryland Medical Center
Baltimore, Maryland · Recruiting
Barnes-Jewish Hospital - St. Louis (Washington University Medical Campus)
St Louis, Missouri · Recruiting
Cooperman Barnabas Medical Center
Livingston, New Jersey · Recruiting
New York-Presbyterian - Weill Cornell Medical Center
New York, New York · Recruiting
Wake Forest School of Medicine
Winston-Salem, North Carolina · Recruiting
University Hospitals Cleveland Medical Center
Cleveland, Ohio · Recruiting
University of Pittsburgh Medical Center (UPMC)
Pittsburgh, Pennsylvania · Recruiting
University of Texas Southwestern Medical Center
Dallas, Texas · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.